Article
Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.
Annals of hepatology - 1 Jan 2026
Jermy Bradley, Brownrigg Jack, Strnad Pavel, Loomba Rohit
Abstract excerpt
INTRODUCTION AND OBJECTIVES: Most investigational treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) show modest anti-fibrotic effects, likely due to a multifactorial aetiology. The Pi*Z mutation in SERPINA1 can lead to proteotoxic liver injury and progressive chronic liver disease. Here, we investigate whether the SERPINA1 Z...
Topics
- Humans
- Disease Progression
- Female
- Male
- alpha 1-Antitrypsin
- Risk Factors
- Middle Aged
- Genetic Predisposition to Disease
- Liver Cirrhosis
- Mutation
- Fatty Liver
